Abstract: The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.

Abstract: Automated systems and methods for evaluating specimens affixed to substrates, such as slides, an exemplary system including a slide imager configured for acquiring a plurality of micro images of a specimen affixed to an substrate, the specimen including a plurality of objects distributed within a three-dimensional volume, and for generating a whole specimen image of the specimen using the micro images, wherein objects contained in the specimen are depicted substantially in focus in the whole specimen image regardless of a z-depth of the respective objects within the specimen. The whole specimen image is stored on a storage medium for subsequent review by a cytotechnologist using a computer-controlled review station including a display and a user interface, wherein the review station user interface is configured such that the cytotechnologist can review and classify the stored whole specimen images.

Abstract: The techniques disclosed herein provide recommendations of content based on user selections of curated review responses. A system can provide a set of curated response candidates and a related question to users providing a review of a product. The set of curated response candidates are selected based on a category that is determined by one or more factors. For example, if a user is to provide a review on a video game, the category can be based on aspects of the video game, such as visual features, game play features, etc. A user can respond to the question by selecting at least one of the curated response candidates. The system can then analyze a data structure that associates the selected response to one or more characteristics to determine characteristics that are preferred by the user. The system can then use the characteristics to recommend other content.

Abstract: A crystalline material processing method includes forming subsurface laser damage at a first average depth position to form cracks in the substrate interior propagating outward from at least one subsurface laser damage pattern, followed by imaging the substrate top surface, analyzing the image to identify a condition indicative of presence of uncracked regions within the substrate, and taking one or more actions responsive to the analyzing. One potential action includes changing an instruction set for producing subsequent laser damage formation (at second or subsequent average depth positions), without necessarily forming additional damage at the first depth position. Another potential action includes forming additional subsurface laser damage at the first depth position.

Abstract: A magnetic flowmeter for sensing process fluid flow includes a flow tube configured to receive the process fluid flow there through and a plurality of electrodes disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. A flow tube liner is provided in the flow tube having an interior surface configured to contact process fluid and an exterior surface mounted to the flow tube. The flow tube liner has at least one adhesion feature in the exterior surface which promotes adhesion between the flow tube liner and the flow tube. A method is also provided.

Abstract: A composite flow tube liner includes a cylindrical substrate and an interior layer. The cylindrical substrate includes a plurality of perforations and is configured for installation within a flow tube assembly of a magnetic flowmeter. The interior layer includes a fluoroelastomer and covers an interior surface of the substrate. The interior layer extends into the perforations of the cylindrical substrate, which secures the fluoroelastomer to the cylindrical substrate.

Abstract: A composite flow tube liner includes a cylindrical substrate and an interior layer. The cylindrical substrate includes a plurality of perforations and is configured for installation within a flow tube assembly of a magnetic flowmeter. The interior layer includes a fluoroelastomer and covers an interior surface of the substrate. The interior layer extends into the perforations of the cylindrical substrate, which secures the fluoroelastomer to the cylindrical substrate.

Abstract: A flowtube assembly for a magnetic flowmeter is provided. The flowtube assembly includes a flowtube configured to receive a flow of process fluid therethrough. A magnetic core is mounted relative to the flowtube and includes a stem extending from the flowtube to a pair of arms. Each of the arms extends away from the stem. A spool having a plurality of magnetic windings is disposed about the stem and spaces the plurality of windings from the flowtube.

Abstract: A method, apparatus (800), and system (900) for a water activated neck seal tension relief device are described. The system (900) includes a liner (902), such as that of a protective suit, and an actuator apparatus (800) disposed within the liner (902). The apparatus (800) includes a resilient member (200) and a coupling (802), the coupling (802) including a body (600) configured to receive a first (810) and a second (808) portion of the resilient member (200). The liner (902), body (600) and resilient member (200) define a substantially circular opening. A restraint (804) is mounted on the body (600) and configured to restrain the second portion (808) of the resilient member (200) in relation to the body (600) to maintain the resilient member (200) in a first position at which the opening has a first diameter (702). The restraint (804) is configured to release the second portion (808) of the resilient member (200) when the restraint (804) is exposed to water.

Abstract: A magnetic flowmeter for sensing process fluid flow is provided. The flowmeter includes a tube configured to receive the process fluid flow therethrough. A plurality of electrodes is disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. Flowmeter electronics are configured to drive a current through at least one electromagnetic coil and to sense a signal developed across a plurality of electrodes disposed to contact process fluid. A flexible circuit module is disposed proximate the tube, and has at least one flexible circuit containing a plurality of electrical traces electrically coupled to the flowmeter electronics. The at least one electromagnetic coil includes a first coil in the flexible circuit module that is coupled to the electrical traces.

Abstract: A flowtube assembly for a magnetic flowmeter is provided. The flowtube assembly includes a flowtube configured to receive a flow of process fluid therethrough. A magnetic core is mounted relative to the flowtube and includes a stem extending from the flowtube to a pair of arms. Each of the arms extends away from the stem. A spool having a plurality of magnetic windings is disposed about the stem and spaces the plurality of windings from the flowtube.

Abstract: A magnetic flowmeter for sensing process fluid flow is provided. The flowmeter includes a tube configured to receive the process fluid flow therethrough. A plurality of electrodes is disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. Flowmeter electronics are configured to drive a current through at least one electromagnetic coil and to sense a signal developed across a plurality of electrodes disposed to contact process fluid. A flexible circuit module is disposed proximate the tube, and has at least one flexible circuit containing a plurality of electrical traces electrically coupled to the flowmeter electronics. The at least one electromagnetic coil includes a first coil in the flexible circuit module that is coupled to the electrical traces.

Abstract: A method and apparatus for separating a first fluid from a fluid mixture. In one embodiment water containing methane is passed through an agitation chamber with a plate at the chamber's proximal and distal ends. Both plates have orifices permitting the mixed fluid to pass into and out of the agitation chamber. In one embodiment, the mixed fluid rotates about its axis of flow through the agitation chamber. In one embodiment, the mixed fluid passes through a separation chamber having a plurality of baffles that promote separation of the methane from the methane/water mixture. In one embodiment, the separated methane is removed from the water in a collection chamber that facilitates gravity separation of the mixed fluids.

Abstract: This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N—N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: A method and apparatus for separating a first fluid from a fluid mixture. In one embodiment water containing methane is passed through an agitation chamber with a plate at the chamber's proximal and distal ends. Both plates have orifices permitting the mixed fluid to pass into and out of the agitation chamber. In one embodiment, the mixed fluid rotates about its axis of flow through the agitation chamber. In one embodiment, the mixed fluid passes through a separation chamber having a plurality of baffles that promote separation of the methane from the methane/water mixture. In one embodiment, the separated methane is removed from the water in a collection chamber that facilitates gravity separation of the mixed fluids.

Abstract: A method and apparatus for separating a first fluid from a fluid mixture. In one embodiment water containing methane is passed through an agitation chamber with a plate at the chamber's proximal and distal ends. Both plates have orifices permitting the mixed fluid to pass into and out of the agitation chamber. In one embodiment, the mixed fluid rotates about its axis of flow through the agitation chamber. In one embodiment, the mixed fluid passes through a separation chamber having a plurality of baffles that promote separation of the methane from the methane/water mixture. In one embodiment, the separated methane is removed from the water in a collection chamber that facilitates gravity separation of the mixed fluids. In one embodiment, liquid hydrocarbon is removed from water.

Abstract: This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N—N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain pentafluorosulpholane-containing compounds of the formula or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain bridged and fused heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, ester solvate or prodrug thereof wherein: L is: (II) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain bridged and fused compounds of the formula G-L-A I or a pharmaceutically acceptable salt, ester of solvate thereof wherein: A is: (I) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.